BCAX

SEC source: 0000950170-24-107660 · ownership.xml · derivative · entry 4

FMR LLC · CIK 0000315066 · See Remark 1

10b5-1 filing: No plan indicated

Ownership: Indirect · F-Prime Capital Partners Life Sciences Fund VII LP

Disclosed balance after: 0

Underlying: Common Stock · 10,818 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: On September 16, 2024, in connection with the completion of the issuer's initial public offering, each share of Series Seed, B, and C Preferred Shares converted on a 1-for-1 basis into shares of Common Stock.

F1 · price: On September 16, 2024, in connection with the completion of the issuer's initial public offering, each share of Series Seed, B, and C Preferred Shares converted on a 1-for-1 basis into shares of Common Stock.

F1 · derivative.exercise_date: On September 16, 2024, in connection with the completion of the issuer's initial public offering, each share of Series Seed, B, and C Preferred Shares converted on a 1-for-1 basis into shares of Common Stock.

F1 · derivative.expiration_date: On September 16, 2024, in connection with the completion of the issuer's initial public offering, each share of Series Seed, B, and C Preferred Shares converted on a 1-for-1 basis into shares of Common Stock.

SEC source: 0000950170-24-107660 · ownership.xml · nonDerivative · entry 3

FMR LLC · CIK 0000315066 · See Remark 1

10b5-1 filing: No plan indicated

Ownership: Indirect · F-Prime Capital Partners Life Sciences Fund VII LP

Disclosed balance after: 1,115,333

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: On September 16, 2024, in connection with the completion of the issuer's initial public offering, each share of Series Seed, B, and C Preferred Shares converted on a 1-for-1 basis into shares of Common Stock.

SEC source: 0000950170-24-107660 · ownership.xml · nonDerivative · entry 2

FMR LLC · CIK 0000315066 · See Remark 1

10b5-1 filing: No plan indicated

Ownership: Indirect · F-Prime Capital Partners Life Sciences Fund VII LP

Disclosed balance after: 723,248

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: On September 16, 2024, in connection with the completion of the issuer's initial public offering, each share of Series Seed, B, and C Preferred Shares converted on a 1-for-1 basis into shares of Common Stock.

SEC source: 0000950170-24-107660 · ownership.xml · nonDerivative · entry 1

FMR LLC · CIK 0000315066 · See Remark 1

10b5-1 filing: No plan indicated

Ownership: Indirect · F-Prime Capital Partners Life Sciences Fund VII LP

Disclosed balance after: 10,818

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: On September 16, 2024, in connection with the completion of the issuer's initial public offering, each share of Series Seed, B, and C Preferred Shares converted on a 1-for-1 basis into shares of Common Stock.

SEC source: 0000950170-24-107661 · ownership.xml · derivative · entry 6

FIL Ltd · CIK 0000318989 · See Remark 1

10b5-1 filing: No plan indicated

Ownership: Indirect · Eight Roads Ventures India Healthcare IV, L.P.

Disclosed balance after: 0

Underlying: Common Stock · 352,876 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: On September 16, 2024, in connection with the completion of the issuer's initial public offering, each share of Series Seed, B, and C Preferred Shares converted on a 1-for-1 basis into shares of Common Stock.

F1 · price: On September 16, 2024, in connection with the completion of the issuer's initial public offering, each share of Series Seed, B, and C Preferred Shares converted on a 1-for-1 basis into shares of Common Stock.

F1 · derivative.exercise_date: On September 16, 2024, in connection with the completion of the issuer's initial public offering, each share of Series Seed, B, and C Preferred Shares converted on a 1-for-1 basis into shares of Common Stock.

F1 · derivative.expiration_date: On September 16, 2024, in connection with the completion of the issuer's initial public offering, each share of Series Seed, B, and C Preferred Shares converted on a 1-for-1 basis into shares of Common Stock.

SEC source: 0000950170-24-107661 · ownership.xml · derivative · entry 5

FIL Ltd · CIK 0000318989 · See Remark 1

10b5-1 filing: No plan indicated

Ownership: Indirect · Eight Roads Ventures India Healthcare IV, L.P.

Disclosed balance after: 0

Underlying: Common Stock · 606,885 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: On September 16, 2024, in connection with the completion of the issuer's initial public offering, each share of Series Seed, B, and C Preferred Shares converted on a 1-for-1 basis into shares of Common Stock.

F1 · price: On September 16, 2024, in connection with the completion of the issuer's initial public offering, each share of Series Seed, B, and C Preferred Shares converted on a 1-for-1 basis into shares of Common Stock.

F1 · derivative.exercise_date: On September 16, 2024, in connection with the completion of the issuer's initial public offering, each share of Series Seed, B, and C Preferred Shares converted on a 1-for-1 basis into shares of Common Stock.

F1 · derivative.expiration_date: On September 16, 2024, in connection with the completion of the issuer's initial public offering, each share of Series Seed, B, and C Preferred Shares converted on a 1-for-1 basis into shares of Common Stock.

SEC source: 0000950170-24-107661 · ownership.xml · derivative · entry 4

FIL Ltd · CIK 0000318989 · See Remark 1

10b5-1 filing: No plan indicated

Ownership: Indirect · Eight Roads Ventures India Healthcare IV, L.P.

Disclosed balance after: 0

Underlying: Common Stock · 54,092 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: On September 16, 2024, in connection with the completion of the issuer's initial public offering, each share of Series Seed, B, and C Preferred Shares converted on a 1-for-1 basis into shares of Common Stock.

F1 · price: On September 16, 2024, in connection with the completion of the issuer's initial public offering, each share of Series Seed, B, and C Preferred Shares converted on a 1-for-1 basis into shares of Common Stock.

F1 · derivative.exercise_date: On September 16, 2024, in connection with the completion of the issuer's initial public offering, each share of Series Seed, B, and C Preferred Shares converted on a 1-for-1 basis into shares of Common Stock.

F1 · derivative.expiration_date: On September 16, 2024, in connection with the completion of the issuer's initial public offering, each share of Series Seed, B, and C Preferred Shares converted on a 1-for-1 basis into shares of Common Stock.

SEC source: 0000950170-24-107661 · ownership.xml · nonDerivative · entry 3

FIL Ltd · CIK 0000318989 · See Remark 1

10b5-1 filing: No plan indicated

Ownership: Indirect · Eight Roads Ventures India Healthcare IV, L.P.

Disclosed balance after: 1,013,853

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: On September 16, 2024, in connection with the completion of the issuer's initial public offering, each share of Series Seed, B, and C Preferred Shares converted on a 1-for-1 basis into shares of Common Stock.

SEC source: 0000950170-24-107661 · ownership.xml · nonDerivative · entry 2

FIL Ltd · CIK 0000318989 · See Remark 1

10b5-1 filing: No plan indicated

Ownership: Indirect · Eight Roads Ventures India Healthcare IV, L.P.

Disclosed balance after: 660,977

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: On September 16, 2024, in connection with the completion of the issuer's initial public offering, each share of Series Seed, B, and C Preferred Shares converted on a 1-for-1 basis into shares of Common Stock.

SEC source: 0000950170-24-107661 · ownership.xml · nonDerivative · entry 1

FIL Ltd · CIK 0000318989 · See Remark 1

10b5-1 filing: No plan indicated

Ownership: Indirect · Eight Roads Ventures India Healthcare IV, L.P.

Disclosed balance after: 54,092

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: On September 16, 2024, in connection with the completion of the issuer's initial public offering, each share of Series Seed, B, and C Preferred Shares converted on a 1-for-1 basis into shares of Common Stock.

SEC source: 0001999371-24-012102 · ownership.xml · derivative · entry 2

TPG GP A, LLC · CIK 0001903793 · Former 10% Owner

BONDERMAN DAVID · CIK 0000860866 · Former 10% Owner

COULTER JAMES G · CIK 0001099776 · Former 10% Owner

WINKELRIED JON · CIK 0001366946 · Former 10% Owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Explanation of Responses

Disclosed balance after: 0

Underlying: Common Stock · 1,960,425 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Pursuant to the Fourth Amended and Restated Certificate of Incorporation of the Issuer, the 18,121,194 shares of Series C Preferred Stock of the Issuer held by TPG Butterfly I automatically converted into 1,960,425 shares of Common Stock upon consummation of the Issuer's initial public offering on September 16, 2024. The shares of Series C Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at a conversion rate (reflecting the 1-for-9.2435 reverse stock split effected on September 5, 2024) equal to one share of Common Stock per 9.2435 shares of Series C Preferred Stock, subject to adjustment.

F3 · price: Pursuant to the Fourth Amended and Restated Certificate of Incorporation of the Issuer, the 18,121,194 shares of Series C Preferred Stock of the Issuer held by TPG Butterfly I automatically converted into 1,960,425 shares of Common Stock upon consummation of the Issuer's initial public offering on September 16, 2024. The shares of Series C Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at a conversion rate (reflecting the 1-for-9.2435 reverse stock split effected on September 5, 2024) equal to one share of Common Stock per 9.2435 shares of Series C Preferred Stock, subject to adjustment.

F3 · derivative.exercise_date: Pursuant to the Fourth Amended and Restated Certificate of Incorporation of the Issuer, the 18,121,194 shares of Series C Preferred Stock of the Issuer held by TPG Butterfly I automatically converted into 1,960,425 shares of Common Stock upon consummation of the Issuer's initial public offering on September 16, 2024. The shares of Series C Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at a conversion rate (reflecting the 1-for-9.2435 reverse stock split effected on September 5, 2024) equal to one share of Common Stock per 9.2435 shares of Series C Preferred Stock, subject to adjustment.

F3 · derivative.expiration_date: Pursuant to the Fourth Amended and Restated Certificate of Incorporation of the Issuer, the 18,121,194 shares of Series C Preferred Stock of the Issuer held by TPG Butterfly I automatically converted into 1,960,425 shares of Common Stock upon consummation of the Issuer's initial public offering on September 16, 2024. The shares of Series C Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at a conversion rate (reflecting the 1-for-9.2435 reverse stock split effected on September 5, 2024) equal to one share of Common Stock per 9.2435 shares of Series C Preferred Stock, subject to adjustment.

F1 · ownership.nature: Each of David Bonderman, James G. Coulter and Jon Winkelried own entities that control TPG GP A, LLC (together with Messrs. Bonderman, Coulter and Winkelried, the "Reporting Persons"), which is the managing member of each of (i) TPG Group Holdings (SBS) Advisors, LLC, which is the general partner of TPG Group Holdings (SBS), L.P., and (ii) Alabama Investments (Parallel) GP, LLC, which is the general partner of each of (a) Alabama Investments (Parallel), LP, (b) Alabama Investments (Parallel) Founder A, LP and (c) Alabama Investments (Parallel) Founder G, LP, which, collectively with TPG Group Holdings (SBS), L.P., Alabama Investments (Parallel), LP and Alabama Investments (Parallel) Founder A, LP, holds 100% of the shares of Class B common stock (which represents a majority of the combined voting power of the common stock) of TPG Inc.

F2 · ownership.nature: TPG Inc. is the sole member of TPG GPCo, LLC, which is the sole member of TPG Holdings II-A, LLC, which is the general partner of TPG Operating Group II, L.P., which is the sole member of TPG Holdings I-A, LLC, which is the general partner of TPG Operating Group I, L.P., which is the sole member of TPG LSI GenPar Advisors, LLC, which is the general partner of TPG LSI GenPar, L.P., which is the sole member of TPG LSI SPV GP, LLC, which is the general partner of TPG LSI Rise Butterfly, L.P. ("TPG Butterfly I"), which directly holds 1,960,425 shares of Common Stock ("Common Stock") of Bicara Therapeutics Inc. (the "Issuer").

F3 · ownership.nature: Pursuant to the Fourth Amended and Restated Certificate of Incorporation of the Issuer, the 18,121,194 shares of Series C Preferred Stock of the Issuer held by TPG Butterfly I automatically converted into 1,960,425 shares of Common Stock upon consummation of the Issuer's initial public offering on September 16, 2024. The shares of Series C Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at a conversion rate (reflecting the 1-for-9.2435 reverse stock split effected on September 5, 2024) equal to one share of Common Stock per 9.2435 shares of Series C Preferred Stock, subject to adjustment.

F4 · ownership.nature: Because of the relationship between the Reporting Persons and TPG Butterfly I, the Reporting Persons may be deemed to beneficially own the securities reported herein to the extent of the greater of their respective direct or indirect pecuniary interests in the profits or capital accounts of TPG Butterfly I. Each of TPG Butterfly I and each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of TPG Butterfly I's or such Reporting Person's pecuniary interest therein, if any.

F5 · ownership.nature: Pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests.

SEC source: 0001999371-24-012102 · ownership.xml · nonDerivative · entry 1

TPG GP A, LLC · CIK 0001903793 · Former 10% Owner

BONDERMAN DAVID · CIK 0000860866 · Former 10% Owner

COULTER JAMES G · CIK 0001099776 · Former 10% Owner

WINKELRIED JON · CIK 0001366946 · Former 10% Owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Explanation of Responses

Disclosed balance after: 1,960,425

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · price: Pursuant to the Fourth Amended and Restated Certificate of Incorporation of the Issuer, the 18,121,194 shares of Series C Preferred Stock of the Issuer held by TPG Butterfly I automatically converted into 1,960,425 shares of Common Stock upon consummation of the Issuer's initial public offering on September 16, 2024. The shares of Series C Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at a conversion rate (reflecting the 1-for-9.2435 reverse stock split effected on September 5, 2024) equal to one share of Common Stock per 9.2435 shares of Series C Preferred Stock, subject to adjustment.

F1 · ownership.nature: Each of David Bonderman, James G. Coulter and Jon Winkelried own entities that control TPG GP A, LLC (together with Messrs. Bonderman, Coulter and Winkelried, the "Reporting Persons"), which is the managing member of each of (i) TPG Group Holdings (SBS) Advisors, LLC, which is the general partner of TPG Group Holdings (SBS), L.P., and (ii) Alabama Investments (Parallel) GP, LLC, which is the general partner of each of (a) Alabama Investments (Parallel), LP, (b) Alabama Investments (Parallel) Founder A, LP and (c) Alabama Investments (Parallel) Founder G, LP, which, collectively with TPG Group Holdings (SBS), L.P., Alabama Investments (Parallel), LP and Alabama Investments (Parallel) Founder A, LP, holds 100% of the shares of Class B common stock (which represents a majority of the combined voting power of the common stock) of TPG Inc.

F2 · ownership.nature: TPG Inc. is the sole member of TPG GPCo, LLC, which is the sole member of TPG Holdings II-A, LLC, which is the general partner of TPG Operating Group II, L.P., which is the sole member of TPG Holdings I-A, LLC, which is the general partner of TPG Operating Group I, L.P., which is the sole member of TPG LSI GenPar Advisors, LLC, which is the general partner of TPG LSI GenPar, L.P., which is the sole member of TPG LSI SPV GP, LLC, which is the general partner of TPG LSI Rise Butterfly, L.P. ("TPG Butterfly I"), which directly holds 1,960,425 shares of Common Stock ("Common Stock") of Bicara Therapeutics Inc. (the "Issuer").

F3 · ownership.nature: Pursuant to the Fourth Amended and Restated Certificate of Incorporation of the Issuer, the 18,121,194 shares of Series C Preferred Stock of the Issuer held by TPG Butterfly I automatically converted into 1,960,425 shares of Common Stock upon consummation of the Issuer's initial public offering on September 16, 2024. The shares of Series C Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at a conversion rate (reflecting the 1-for-9.2435 reverse stock split effected on September 5, 2024) equal to one share of Common Stock per 9.2435 shares of Series C Preferred Stock, subject to adjustment.

F4 · ownership.nature: Because of the relationship between the Reporting Persons and TPG Butterfly I, the Reporting Persons may be deemed to beneficially own the securities reported herein to the extent of the greater of their respective direct or indirect pecuniary interests in the profits or capital accounts of TPG Butterfly I. Each of TPG Butterfly I and each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of TPG Butterfly I's or such Reporting Person's pecuniary interest therein, if any.

F5 · ownership.nature: Pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests.

SEC source: 0001415889-24-023653 · form4-09182024_100931.xml · derivative · entry 8

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner

RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner

RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director

Kolchinsky Peter · CIK 0001384859 · Director · 10% owner

Shah Rajeev M. · CIK 0001619841 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 0

Underlying: Common Stock · 1,172,334 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") converted into shares of Common Stock of the Issuer on a one-for-9.2435 basis without payment of further consideration. Upon the closing of the Issuer's initial public offering (the "IPO"), the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date.

F1 · price: Each share of Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") converted into shares of Common Stock of the Issuer on a one-for-9.2435 basis without payment of further consideration. Upon the closing of the Issuer's initial public offering (the "IPO"), the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Each share of Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") converted into shares of Common Stock of the Issuer on a one-for-9.2435 basis without payment of further consideration. Upon the closing of the Issuer's initial public offering (the "IPO"), the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Each share of Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") converted into shares of Common Stock of the Issuer on a one-for-9.2435 basis without payment of further consideration. Upon the closing of the Issuer's initial public offering (the "IPO"), the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date.

F2 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.

F4 · ownership.nature: Held directly by Nexus Fund III.

SEC source: 0001415889-24-023653 · form4-09182024_100931.xml · derivative · entry 7

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner

RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner

RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director

Kolchinsky Peter · CIK 0001384859 · Director · 10% owner

Shah Rajeev M. · CIK 0001619841 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 0

Underlying: Common Stock · 631,256 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") converted into shares of Common Stock of the Issuer on a one-for-9.2435 basis without payment of further consideration. Upon the closing of the Issuer's initial public offering (the "IPO"), the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date.

F1 · price: Each share of Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") converted into shares of Common Stock of the Issuer on a one-for-9.2435 basis without payment of further consideration. Upon the closing of the Issuer's initial public offering (the "IPO"), the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Each share of Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") converted into shares of Common Stock of the Issuer on a one-for-9.2435 basis without payment of further consideration. Upon the closing of the Issuer's initial public offering (the "IPO"), the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Each share of Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") converted into shares of Common Stock of the Issuer on a one-for-9.2435 basis without payment of further consideration. Upon the closing of the Issuer's initial public offering (the "IPO"), the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date.

F2 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.

F3 · ownership.nature: Held directly by the Fund.

SEC source: 0001415889-24-023653 · form4-09182024_100931.xml · derivative · entry 6

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner

RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner

RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director

Kolchinsky Peter · CIK 0001384859 · Director · 10% owner

Shah Rajeev M. · CIK 0001619841 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 0

Underlying: Common Stock · 1,327,761 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") converted into shares of Common Stock of the Issuer on a one-for-9.2435 basis without payment of further consideration. Upon the closing of the Issuer's initial public offering (the "IPO"), the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date.

F1 · price: Each share of Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") converted into shares of Common Stock of the Issuer on a one-for-9.2435 basis without payment of further consideration. Upon the closing of the Issuer's initial public offering (the "IPO"), the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Each share of Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") converted into shares of Common Stock of the Issuer on a one-for-9.2435 basis without payment of further consideration. Upon the closing of the Issuer's initial public offering (the "IPO"), the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Each share of Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") converted into shares of Common Stock of the Issuer on a one-for-9.2435 basis without payment of further consideration. Upon the closing of the Issuer's initial public offering (the "IPO"), the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date.

F2 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.

F4 · ownership.nature: Held directly by Nexus Fund III.

SEC source: 0001415889-24-023653 · form4-09182024_100931.xml · derivative · entry 5

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner

RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner

RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director

Kolchinsky Peter · CIK 0001384859 · Director · 10% owner

Shah Rajeev M. · CIK 0001619841 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 0

Underlying: Common Stock · 1,991,642 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") converted into shares of Common Stock of the Issuer on a one-for-9.2435 basis without payment of further consideration. Upon the closing of the Issuer's initial public offering (the "IPO"), the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date.

F1 · price: Each share of Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") converted into shares of Common Stock of the Issuer on a one-for-9.2435 basis without payment of further consideration. Upon the closing of the Issuer's initial public offering (the "IPO"), the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Each share of Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") converted into shares of Common Stock of the Issuer on a one-for-9.2435 basis without payment of further consideration. Upon the closing of the Issuer's initial public offering (the "IPO"), the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Each share of Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") converted into shares of Common Stock of the Issuer on a one-for-9.2435 basis without payment of further consideration. Upon the closing of the Issuer's initial public offering (the "IPO"), the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date.

F2 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.

F3 · ownership.nature: Held directly by the Fund.

SEC source: 0001415889-24-023653 · form4-09182024_100931.xml · nonDerivative · entry 4

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner

RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner

RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director

Kolchinsky Peter · CIK 0001384859 · Director · 10% owner

Shah Rajeev M. · CIK 0001619841 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 2,652,575

F2 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.

F4 · ownership.nature: Held directly by Nexus Fund III.

SEC source: 0001415889-24-023653 · form4-09182024_100931.xml · nonDerivative · entry 3

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner

RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner

RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director

Kolchinsky Peter · CIK 0001384859 · Director · 10% owner

Shah Rajeev M. · CIK 0001619841 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 4,303,418

F2 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.

F3 · ownership.nature: Held directly by the Fund.

SEC source: 0001415889-24-023653 · form4-09182024_100931.xml · nonDerivative · entry 2

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner

RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner

RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director

Kolchinsky Peter · CIK 0001384859 · Director · 10% owner

Shah Rajeev M. · CIK 0001619841 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 2,500,095

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") converted into shares of Common Stock of the Issuer on a one-for-9.2435 basis without payment of further consideration. Upon the closing of the Issuer's initial public offering (the "IPO"), the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date.

F2 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.

F4 · ownership.nature: Held directly by Nexus Fund III.

SEC source: 0001415889-24-023653 · form4-09182024_100931.xml · nonDerivative · entry 1

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner

RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner

RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director

Kolchinsky Peter · CIK 0001384859 · Director · 10% owner

Shah Rajeev M. · CIK 0001619841 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 2,622,898

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") converted into shares of Common Stock of the Issuer on a one-for-9.2435 basis without payment of further consideration. Upon the closing of the Issuer's initial public offering (the "IPO"), the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date.

F2 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.

F3 · ownership.nature: Held directly by the Fund.

SEC source: 0000950170-24-106866 · ownership.xml · derivative · entry 5

Mazumdar-Shaw Kiran · CIK 0002034672 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,746

Underlying: Common Stock · 23,746 shares

Expires 2034-09-12

F6 · derivative.exercise_date: The shares underlying this option shall vest upon the earlier of (i) August 16, 2025 and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date.

SEC source: 0001415889-24-023452 · form4-09162024_090949.xml · derivative · entry 1

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner

RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner

RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director

Kolchinsky Peter · CIK 0001384859 · Director · 10% owner

Shah Rajeev M. · CIK 0001619841 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 23,746

Underlying: Common Stock · 23,746 shares

Expires 2034-09-12

F1 · derivative.exercise_date: The shares underlying this option shall vest upon the earlier of (i) August 16, 2025 and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date.

F2 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.

F3 · ownership.nature: Jake Simson is a Partner of the Adviser who serves on the Issuer's board of directors. Under Dr. Simson's arrangement with the Adviser, Dr. Simson holds the option for the benefit of the Fund and the Nexus Fund III. Dr. Simson is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund and the Nexus Fund III to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the option and underlying common stock.

SEC source: 0000950170-24-106881 · ownership.xml · derivative · entry 1

LONBERG NILS · CIK 0001214506 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,746

Underlying: Common Stock · 23,746 shares

Expires 2034-09-12

F1 · derivative.exercise_date: The shares underlying this option shall vest upon the earlier of (i) August 16, 2025 and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date.

SEC source: 0000950170-24-106880 · ownership.xml · derivative · entry 1

Simson Jake · CIK 0001863094 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,746

Underlying: Common Stock · 23,746 shares

Expires 2034-09-12

F1 · derivative.exercise_date: The shares underlying this option shall vest upon the earlier of (i) August 16, 2025 and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date.

F2 · ownership.direct: Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the option for the benefit of the R.A. Capital Healthcare Fund, L.P. (the "Fund") and R.A. Capital Nexus Fund III, L.P. (the "Nexus Fund III"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund and Nexus Fund III to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock.

SEC source: 0000950170-24-106873 · ownership.xml · derivative · entry 1

Haviland Kate · CIK 0001663022 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,746

Underlying: Common Stock · 23,746 shares

Expires 2034-09-12

F1 · derivative.exercise_date: The shares underlying this option shall vest upon the earlier of (i) August 16, 2025 and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date.

SEC source: 0000950170-24-106868 · ownership.xml · derivative · entry 1

Robertson Scott M. · CIK 0001882035 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,746

Underlying: Common Stock · 23,746 shares

Expires 2034-09-12

F1 · derivative.exercise_date: The shares underlying this option shall vest upon the earlier of (i) August 16, 2025 and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date.